1. Clinical & Scientific Overview
Silver Sulfadiazine (1% Topical Burn Antimicrobial Cream) (TIP-MED-000261, Reference Code [12.29]) is classified under
Dermatological & Topical Antiseptic Preparations (Ch 12) as a Topical Heavy-Metal / Sulfonamide Burn Antimicrobial.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.29], p. 169): Silverex, Burnol-SSD, Silvirin — Strengths & Dosage Forms: Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
3. Mechanism of Action & Pharmacodynamics
Slowly releases bactericidal silver ions (Ag+) that bind bacterial DNA and cell membranes, combined with sulfadiazine competitive inhibition of bacterial dihydropteroate synthase; active against Pseudomonas aeruginosa, Staphylococcus aureus, and Candida.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and treatment of wound sepsis in second- and third-degree thermal burns
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: After cleansing and debriding burn wound, apply a sterile 3–5 mm thick layer over the burn surface 1–2 times daily using a sterile gloved hand or spatula. • Paediatric: Children >2 months: Apply 3-5 mm layer 1-2 times daily. CONTRAINDICATED in preterm infants and neonates <2 months.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Term pregnancy at or near labour, preterm infants, and neonates <2 months of age (sulfonamide displaces bilirubin from albumin -> kernicterus); known sulfonamide hypersensitivity; severe G6PD deficiency (haemolysis risk on large burns). • Precautions: Transient leukopenia/neutropenia commonly occurs on Days 2–4 of extensive burn application (usually recovers spontaneously despite continued therapy); avoid applying to the face (risk of grey argyria pigmentation on sun exposure); delays epithelialisation if continued after eschar separation.
Key Clinical Precautions: Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
8. Adverse Effects Profile
- Transient local burning, brownish-grey pseudoeschar discolouration of wound bed, reversible leukopenia (Days 2-4).
- Stevens-Johnson syndrome / TEN (sulfonamide component), haemolytic anaemia in G6PD deficiency, argyria (prolonged large-area use), kernicterus in neonates.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Topical proteolytic enzymatic debriding agents (Collagenase, Papain-Urea) -> silver ions inactivate enzymes; Povidone-iodine -> chemical incompatibility
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Keep burned area covered with a 3-5 mm layer of cream at all times (reapply to any area rubbed off by dressings); yellowish-grey film on wound surface is normal reaction of silver with wound fluid, not pus.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.29] (p. 169)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.6]-CMP155 Adapalene 0.1% Gel, Benzoyl Peroxide 2.5%–5% Gel & Luliconazole 1% — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.23]-CMP168 Gamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol — Topical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pedicu
- [12.26]-C169 Clobetasol Propionate — Potent (Class II/III) Fluorinated Topical Corticosteroid
- [12.26]-CMP170 Mometasone Furoate 0.1%, Tacrolimus 0.03%/0.1% Ointment, Calcipotriol & Salicylic Acid / Coal Tar — Potent (Class II/III) Fluorinated Topical Corticosteroid